About tlcr

Manuscript Submission

Advertising

Contact us

Focused Issues more

Vol 5, No 5 (Oct 2016): Liquid Biopsy in Lung Cancer More >>
Vol 5, No 1(Feb 2016): Small Cell Lung Cancer More >>
Vol 5, No 3(June 2016): The role of Nurses and Allied Health Professionals in lung cancer and... More >>

Sponsored by

Translational Lung Cancer Research is sponsored by Nanjing General Hospital of Nanjing Military Command, Nanjing, China

Sponsored by

Review Article

Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring
David Pérez-Callejo, Atocha Romero, Mariano Provencio, María Torrente
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps
Exosomes genetic cargo in lung cancer: a truly Pandora’s box
Pablo Reclusa, Rafael Sirera, Antonio Araujo, Marco Giallombardo, Anna Valentino, Laure Sorber, Ignacio Gil Bazo, Patrick Pauwels, Christian Rolfo
Methylation analyses in liquid biopsy
Delphine Lissa, Ana I. Robles
Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients
Umberto Malapelle, Pasquale Pisapia, Danilo Rocco, Riccardo Smeraglio, Maria di Spirito, Claudio Bellevicine, Giancarlo Troncone
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
Mónica Garzón, Sergi Villatoro, Cristina Teixidó, Clara Mayo, Alejandro Martínez, Maria de los Llanos Gil, Santiago Viteri, Daniela Morales-Espinosa, Rafael Rosell
Liquid biopsy in early stage lung cancer
Cristina Pérez-Ramírez, Marisa Cañadas-Garre, Ana I. Robles, Miguel Ángel Molina, María José Faus-Dáder, Miguel Ángel Calleja-Hernández
Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients
Cristina Aguado, Ana Giménez-Capitán, Niki Karachaliou, Ana Pérez-Rosado, Santiago Viteri, Daniela Morales-Espinosa, Rafael Rosell

Case Report

Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report
Clara Mayo de las Casas, Maria Gonzalez-Cao, Santiago Viteri Ramirez, Nuria Jordana Ariza, Ariadna Balada, Mónica Garzón, Cristina Teixidó, Niki Karachaliou, Daniela Morales-Espinosa, Miguel Ángel Molina-Vila, Rafael Rosell

Maintenance Therapy

Maintenance therapy in non-small cell lung cancer
Gerald Schmid-Bindert

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?
Yoshihisa Kobayashi, Tetsuya Mitsudomi
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach
Javier de Castro Carpeño, Cristóbal Belda-Iniesta
Irreversible EGFR-TKIs: dreaming perfection
Lorenza Landi, Federico Cappuzzo
Angiogenesis in cancer: anti-VEGF escape mechanisms
Gerald W. Prager, Marina Poettler, Matthias Unseld, Christoph C. Zielinski
MET inhibition in lung cancer
Jessica Menis, Matteo Giaj Levra, Silvia Novello
Activated RET and ROS: two new driver mutations in lung adenocarcinoma
Marc Bos, Masyar Gardizi, Hans-Ulrich Schildhaus, Reinhard Buettner, Juergen Wolf
Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
Potential toxicities of prophylactic cranial irradiation
Frank A. Giordano, Grit Welzel, Yasser Abo-Madyan, Frederik Wenz
ALK and ROS1 as a joint target for the treatment of lung cancer: a review
Raimon Puig de la Bellacasa, Niki Karachaliou, Roger Estrada-Tejedor, Jordi Teixidó, Carlota Costa, José I. Borrell
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches
Ana Christina Garrido-Castro, Enriqueta Felip
From tissue to molecular phenotyping: Pre-analytical requirements
Thomas R. Muley, Felix JF. Herth, Philipp A. Schnabel, Hendrik Dienemann, Michael Meister
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
José Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, Rafael Rosell
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Are three doses of SABR (stereotactic ablative radiotherapy) more effective than 30 doses of conventional radiotherapy?
Anna O. Simeonova, Katharina Fleckenstein, Hans-Jörg Wertz, Judit Boda-Heggemann, Frederik Wenz
Cetuximab in non-small-cell lung cancer
Robert Pirker, Martin Filipits
FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications
Hans-Ulrich Schildhaus, Lucia Nogova, Jürgen Wolf, Reinhard Buettner
MET inhibitors in combination with other therapies in non-small cell lung cancer
Sukhmani Padda, Joel W. Neal, Heather A. Wakelee
Adaptive resistance to targeted therapies in cancer
Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa, Carlota Costa, Miguel Angel Molina, Irene Sansano, Amaya Gasco, Santiago Viteri, Bartomeu Massuti, Jia Wei, María González Cao, Alejandro Martínez Bueno
Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
Rathi N. Pillai, Suresh S. Ramalingam

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Original Article

BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.


Review Article



Case Report